These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Update: adverse events associated with anthrax prophylaxis among postal employees--New Jersey, New York City, and the District of Columbia metropolitan area, 2001. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2001 Nov; 50(47):1051-4. PubMed ID: 11808926 [TBL] [Abstract][Full Text] [Related]
27. Extensive cutaneous anthrax in an immunocompetent patient. Karpouzis A; Panopoulou M; Bazzano G; Grapsa A; Maltezos E; Ktenidou-Kartali S; Kouskoukis C Eur J Dermatol; 2007; 17(5):443-5. PubMed ID: 17673392 [TBL] [Abstract][Full Text] [Related]
29. Anthrax aftermath: adverse drug reactions, vaccine controversy undercut CDC extended treatment offer. Evans G ED Manag; 2002 Mar; 14(3):suppl 1-4. PubMed ID: 11912887 [No Abstract] [Full Text] [Related]
30. [The ABCs on anthrax for health personnel]. Valdespino-Gómez JL; García-García ML Salud Publica Mex; 2001; 43(6):604-13. PubMed ID: 11816237 [TBL] [Abstract][Full Text] [Related]
31. Antitoxin Treatment of Inhalation Anthrax: A Systematic Review. Huang E; Pillai SK; Bower WA; Hendricks KA; Guarnizo JT; Hoyle JD; Gorman SE; Boyer AE; Quinn CP; Meaney-Delman D Health Secur; 2015; 13(6):365-77. PubMed ID: 26690378 [TBL] [Abstract][Full Text] [Related]
32. [Anthrax due to deliberate infection]. van Dissel JT; Kullberg BJ; van den Berg PC; van Steenbergen JE Ned Tijdschr Geneeskd; 2001 Dec; 145(49):2366-71. PubMed ID: 11770263 [TBL] [Abstract][Full Text] [Related]
33. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax. Tierney BC; Martin SW; Franzke LH; Marano N; Reissman DB; Louchart RD; Goff JA; Rosenstein NE; Sever JL; McNeil MM; Clin Infect Dis; 2003 Oct; 37(7):905-11. PubMed ID: 13130401 [TBL] [Abstract][Full Text] [Related]
34. [Should patients with a prosthetic joint be given antibiotic prophylaxis for a (suspected) bacterial infection]. Kaandorp CJ Ned Tijdschr Geneeskd; 2002 Jan; 146(3):137. PubMed ID: 11826674 [No Abstract] [Full Text] [Related]
35. Update: Cutaneous anthrax in a laboratory worker--Texas, 2002. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Jun; 51(22):482. PubMed ID: 12064454 [TBL] [Abstract][Full Text] [Related]
37. Characteristics of cutaneous anthrax in Turkey. Baykam N; Ergonul O; Ulu A; Eren S; Celikbas A; Eroglu M; Dokuzoguz B J Infect Dev Ctries; 2009 Sep; 3(8):599-603. PubMed ID: 19801802 [TBL] [Abstract][Full Text] [Related]
38. More on anthrax exposure case report. McFee RB; Howell JT J Am Osteopath Assoc; 2002 Jul; 102(7):362-3; author reply 363-4. PubMed ID: 12138949 [No Abstract] [Full Text] [Related]
39. Raxibacumab for anthrax. Med Lett Drugs Ther; 2013 Apr; 55(1413):27-8. PubMed ID: 23545582 [No Abstract] [Full Text] [Related]
40. Recognition and management of bioterrorism infections. O'Brien KK; Higdon ML; Halverson JJ Am Fam Physician; 2003 May; 67(9):1927-34. PubMed ID: 12751654 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]